August 1, 2019 8:30am

The oversold are conspicuous after yesterday’s 37 of 45 (covered) declines

Beware Q2 earnings’ “LPS” <loss-per-share> perp walk: Intellia Therapeutics (NTLA), Verastem Oncology (VSTM), BioMarin Pharmaceuticals (BMRN), Ultragenyx Pharmaceuticals (RARE) and Sage Therapeutics (SAGE)

Pre-open indications: Glaring bottoms except for those reporting

Every day, I “make my bones”; it’s time for you to step-up for continued access to what one industry CEO calls the “bible” for investing in the RegMed, gene and cell therapy sector.  

Members only. Please login.